Related Experiment Video
Updated: May 29, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Pregabalin in acute and chronic pain
Dalim Kumar Baidya1, Anil Agarwal, Puneet Khanna
1Department of Anaesthesia and Intensive Care, All India Institute of Medical Sciences, New Delhi, India.
Journal of Anaesthesiology, Clinical Pharmacology
|September 8, 2011
Summary
Pregabalin, a gamma-amino-butyric acid analog, effectively reduces opioid use in acute postoperative pain but doesn't consistently lower pain intensity. Further research is needed for its role in chronic pain and more complex surgeries.
Area of Science:
- Pharmacology
- Anesthesiology
- Pain Management
Background:
- Pregabalin is a gamma-amino-butyric acid analog with demonstrated efficacy in neuropathic, incisional, and inflammatory pain models.
- Gabapentinoids, including pregabalin, are increasingly utilized in multimodal perioperative analgesia.
Purpose of the Study:
- To review the role of pregabalin in managing acute postoperative pain and chronic pain syndromes.
- To evaluate the evidence for perioperative pregabalin administration in reducing opioid consumption and adverse effects.
Main Methods:
- Review of randomized controlled trials and meta-analyses.
- Analysis of pregabalin's effects on pain intensity, opioid use, and adverse events in surgical settings.
Main Results:
- Perioperative pregabalin reduces opioid consumption and related adverse effects within 24 hours post-surgery.
- Postoperative pain intensity reduction is inconsistent; higher doses are linked to adverse effects like sedation and dizziness.
- Benefits are currently limited to less painful surgeries (laparoscopic, gynecological, daycare).
Conclusions:
- Pregabalin shows promise in reducing opioid burden in specific perioperative contexts.
- Further studies are required to determine its efficacy in preventing chronic pain, managing more severe surgical pain, and establishing optimal dosing.
- Pregabalin's efficacy is well-established for chronic pain conditions such as painful diabetic neuropathy and fibromyalgia.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:20Pain
Pain serves as a critical warning signal that alerts the body to potential or actual harm. When mechanical pressure on the skin is intense, such as from a sharp pinch, the sensation transitions from touch to pain. Similarly, extreme temperatures, like a hot pot handle, convert the sensation of heat into pain. Pain can also result from overstimulation of other senses, such as blinding light, loud noise, or the intense heat from habañero peppers. This ability to sense pain is essential for...
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...